Aerie Pharmaceuticals, Inc. (AERI) Rating Reiterated by Mizuho
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)‘s stock had its “buy” rating reissued by stock analysts at Mizuho in a research report issued to clients and investors on Friday.
Several other research firms have also recently commented on AERI. Canaccord Genuity reissued a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Friday, September 22nd. Zacks Investment Research cut Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $62.00 price objective on shares of Aerie Pharmaceuticals in a research note on Wednesday, October 11th. Stifel Nicolaus reaffirmed a “buy” rating and set a $70.00 price objective on shares of Aerie Pharmaceuticals in a research note on Friday, July 28th. Finally, BidaskClub raised Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, July 24th. One research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the stock. Aerie Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $69.71.
Aerie Pharmaceuticals (NASDAQ:AERI) traded up $1.15 during midday trading on Friday, hitting $64.85. The stock had a trading volume of 403,663 shares, compared to its average volume of 780,646. Aerie Pharmaceuticals has a one year low of $32.35 and a one year high of $66.25. The company has a quick ratio of 22.45, a current ratio of 22.44 and a debt-to-equity ratio of 0.67.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/11/05/aerie-pharmaceuticals-inc-aeri-rating-reiterated-by-mizuho.html.
A number of hedge funds have recently bought and sold shares of AERI. UBS Asset Management Americas Inc. lifted its holdings in Aerie Pharmaceuticals by 97.3% during the first quarter. UBS Asset Management Americas Inc. now owns 12,430 shares of the company’s stock worth $564,000 after acquiring an additional 6,130 shares in the last quarter. Karp Capital Management Corp bought a new position in Aerie Pharmaceuticals during the first quarter worth about $213,000. FMR LLC lifted its holdings in shares of Aerie Pharmaceuticals by 178.7% in the first quarter. FMR LLC now owns 320,500 shares of the company’s stock valued at $14,535,000 after purchasing an additional 205,500 shares in the last quarter. Teachers Advisors LLC lifted its holdings in shares of Aerie Pharmaceuticals by 5.1% in the first quarter. Teachers Advisors LLC now owns 49,726 shares of the company’s stock valued at $2,255,000 after purchasing an additional 2,402 shares in the last quarter. Finally, California Public Employees Retirement System bought a new stake in shares of Aerie Pharmaceuticals in the first quarter valued at about $231,000. Hedge funds and other institutional investors own 94.71% of the company’s stock.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.